Therapeutic use for treating of leukemia

1. A method of treating leukemia in a patient comprising administering to said patient the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)-urea or a pharmaceutically acceptable salt thereof, wherein the administration is a route selected from the group consisting of an intraperitoneal route, an intravenous route followed by an intraperitoneal route, and an intravenous route followed by an oral route, further comprising administering said compound in combination with daunorubicin.

2. The method according to claim 1 wherein the leukemia is selected from AML or CML.

3. A method of treating leukemia in a patient comprising administering to said patient the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)-urea or a pharmaceutically acceptable salt thereof, wherein the administration is a route selected from the group consisting of an intraperitoneal route, an intravenous route followed by an intraperitoneal route, and an intravenous route followed by an oral route, further comprising administering said compound in combination with daunorubicin and cytosine arabinoside.

4. The method according to claim 3 wherein the leukemia is selected from AML or CML.

5. The method of claim 1 , wherein the administration route is intraperitoneal.

6. The method of claim 1 , wherein the administration route is intravenous followed by an intraperitoneal route.

7. The method of claim 1 , wherein the administration route is intravenous followed by an oral route.

8. The method of claim 3 , wherein the administration route is intraperitoneal.

9. The method of claim 3 , wherein the administration route is intravenous followed by an intraperitoneal route.

10. The method of claim 3 , wherein the administration route is intravenous followed by an oral route.